 |
|
|
| |
A Phase 3 Randomized Controlled Clinical Trial of Bictegravir in a Fixed Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Naïve Adults at Week 48
|
| |
| |
Reported by Jules Levin
9th IAS Conference on HIV Science (IAS 2017) 23-26 July 2017 | Paris, France
Joel Gallant,1 Adriano Lazzarin,2 Anthony Mills,3 Chloe Orkin,4 Daniel Podzamczer,5 Pablo Tebas,6 Pierre-Marie Girard,7 Indira Brar,8 Eric Daar,9 David Wohl,10 Jurgen Rockstroh,11 Xuelian Wei,12 Kirsten White,12 Hal Martin,12 Erin Quirk,12 Andrew Cheng12
1Southwest CARE Center, Santa Fe, New Mexico, USA; 2IRCCS Ospedale San Raffaele SrL, Milan, Italy; 3Mills Clinical Research, Los Angeles, California, USA; 4Barts Health NHS Trust, Royal London Hospital, Ambrose King Centre, London, UK; 5Hospital Universitari de Bellvitge, Barcelona, Spain; 6University of Pennsylvania, Philadelphia, Pennsylvania, USA; 7Hopital Saint Antoine, Paris, France; 8Henry Ford Hospital, Detroit, Michigan, USA; 9Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA; 10University of North Carolina at Chapel Hill, North Carolina, USA; 11University Hospital Bonn, Germany; 12Gilead Sciences, Inc., Foster City, California, USA
|
| |
|
|
|
|
|
